We tested this hypothesis by analyzing a dataset of patients with pathogenic BRCA2-mutant ovarian tumors and found that low APE1 expression in the tumors correlated with worse progression-free survival in BRCA2-mutation carriers (Fig. 5l). The gene discussed is APEX1; the disease is ovarian neoplasm.